Revolution Medicines cuts target price to $247 from $272
RVMD•Morgan Stanley cut its target price for Revolution Medicines to $247 from $272.
Related News
Rezolute's Ersodetug meets primary endpoint in Phase 3 tumor hyperinsulinism trial
RZLT•
Kohl's target price raised to $18 from $15 by Morgan Stanley
KSS•
Dollar set for best week in two months as yen tests 160
TLT•
Axsome Therapeutics: Morgan Stanley cuts target price to $223 from $249
AXSM•
Acadia Pharmaceuticals Inc.: Morgan Stanley cuts target price to $24 from $28
ACAD•